-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Biogen, Raises Price Target to $260

Benzinga·08/25/2026 13:32:10
Listen to the news
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $240 to $260.